Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
Abstract Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort study. Patients with pathology confirmed mCRC...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/94c4253e2ad34466ac4871891f1989f1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:94c4253e2ad34466ac4871891f1989f1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:94c4253e2ad34466ac4871891f1989f12021-12-02T16:06:41ZPreference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread10.1038/s41598-021-94968-x2045-2322https://doaj.org/article/94c4253e2ad34466ac4871891f1989f12021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94968-xhttps://doaj.org/toc/2045-2322Abstract Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort study. Patients with pathology confirmed mCRC and administered with regorafenib for > 3 weeks were enrolled. Patients with good response were defined to have progression-free survival (PFS) of ≥ 4 months. The Kaplan–Meier plot was used to analyze survival. A Cox proportional hazards model was used to analyze univariate and multivariate prognostic factors and was visualized using forest plot. A clustering heatmap was used to classify patients according to responses. The decision tree and nomogram were used to construct the approaching algorithm. A total of 613 patients was analyzed. The median PFS and overall survival (OS) were 2.7 and 10.6 months, respectively. The partial response and stable disease rate are 2.4% and 36.4%. The interval between metastasis (M1) and regorafenib, metastatic status (number, liver, and brain), and CEA level were independent prognostics factors of PFS that classifies patients into three groups: good, bad and modest-1/modest-2 group with PFS > = 4 months rates of 51%, 20%, 39% and 30%, respectively. Results were used to develop the decision tree and nomogram for approaching patients indicated with regorafenib. The preference criteria for regorafenib in treating patients with refractory mCRC are small tumor burden (CEA), slow growth (interval between metastasis and regorafenib) and poor/scanty spread (metastatic status: number and sites of metastasis): The 3S rules. TRIAL registration ClinicalTrials.gov Identifier: NCT03829852; Date of first registration (February 11, 2019).Hung-Chih HsuKuo-Cheng HuangWei-Shone ChenJeng-Kai JiangShung-Haur YangHuann-Sheng WangShih-Ching ChangYuan-Tzu LanChun-Chi LinHung-Hsin LinSheng-Chieh HuangHou-Hsuan ChengTsai-Sheng YangChien-Chih ChenYee ChaoHao-Wei TengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Hung-Chih Hsu Kuo-Cheng Huang Wei-Shone Chen Jeng-Kai Jiang Shung-Haur Yang Huann-Sheng Wang Shih-Ching Chang Yuan-Tzu Lan Chun-Chi Lin Hung-Hsin Lin Sheng-Chieh Huang Hou-Hsuan Cheng Tsai-Sheng Yang Chien-Chih Chen Yee Chao Hao-Wei Teng Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| description |
Abstract Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort study. Patients with pathology confirmed mCRC and administered with regorafenib for > 3 weeks were enrolled. Patients with good response were defined to have progression-free survival (PFS) of ≥ 4 months. The Kaplan–Meier plot was used to analyze survival. A Cox proportional hazards model was used to analyze univariate and multivariate prognostic factors and was visualized using forest plot. A clustering heatmap was used to classify patients according to responses. The decision tree and nomogram were used to construct the approaching algorithm. A total of 613 patients was analyzed. The median PFS and overall survival (OS) were 2.7 and 10.6 months, respectively. The partial response and stable disease rate are 2.4% and 36.4%. The interval between metastasis (M1) and regorafenib, metastatic status (number, liver, and brain), and CEA level were independent prognostics factors of PFS that classifies patients into three groups: good, bad and modest-1/modest-2 group with PFS > = 4 months rates of 51%, 20%, 39% and 30%, respectively. Results were used to develop the decision tree and nomogram for approaching patients indicated with regorafenib. The preference criteria for regorafenib in treating patients with refractory mCRC are small tumor burden (CEA), slow growth (interval between metastasis and regorafenib) and poor/scanty spread (metastatic status: number and sites of metastasis): The 3S rules. TRIAL registration ClinicalTrials.gov Identifier: NCT03829852; Date of first registration (February 11, 2019). |
| format |
article |
| author |
Hung-Chih Hsu Kuo-Cheng Huang Wei-Shone Chen Jeng-Kai Jiang Shung-Haur Yang Huann-Sheng Wang Shih-Ching Chang Yuan-Tzu Lan Chun-Chi Lin Hung-Hsin Lin Sheng-Chieh Huang Hou-Hsuan Cheng Tsai-Sheng Yang Chien-Chih Chen Yee Chao Hao-Wei Teng |
| author_facet |
Hung-Chih Hsu Kuo-Cheng Huang Wei-Shone Chen Jeng-Kai Jiang Shung-Haur Yang Huann-Sheng Wang Shih-Ching Chang Yuan-Tzu Lan Chun-Chi Lin Hung-Hsin Lin Sheng-Chieh Huang Hou-Hsuan Cheng Tsai-Sheng Yang Chien-Chih Chen Yee Chao Hao-Wei Teng |
| author_sort |
Hung-Chih Hsu |
| title |
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| title_short |
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| title_full |
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| title_fullStr |
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| title_full_unstemmed |
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| title_sort |
preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/94c4253e2ad34466ac4871891f1989f1 |
| work_keys_str_mv |
AT hungchihhsu preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT kuochenghuang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT weishonechen preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT jengkaijiang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT shunghauryang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT huannshengwang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT shihchingchang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT yuantzulan preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT chunchilin preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT hunghsinlin preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT shengchiehhuang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT houhsuancheng preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT tsaishengyang preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT chienchihchen preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT yeechao preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread AT haoweiteng preferencecriteriaforregorafenibintreatingrefractorymetastaticcolorectalcancerarethesmalltumorburdenslowgrowthandpoorscantyspread |
| _version_ |
1718384916158218240 |